![]() DQP-997-74 structure
|
Common Name | DQP-997-74 | ||
---|---|---|---|---|
CAS Number | 2377187-09-0 | Molecular Weight | 570.37 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C28H19Cl2F2N3O4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of DQP-997-74DQP-997-74 (compound 2i) is a selective inhibitor of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with Blood-brain permeability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases[1]. |
Name | DQP-997-74 |
---|
Description | DQP-997-74 (compound 2i) is a selective inhibitor of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with Blood-brain permeability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases[1]. |
---|---|
Related Catalog | |
Target |
IC50: 0.069 μM (GluN2C), 0.035 μM (GluN2D), 5.2 μM (GluN2A), 16 μM (GluN2B)[1] |
References |
Molecular Formula | C28H19Cl2F2N3O4 |
---|---|
Molecular Weight | 570.37 |